March 31, 2005 - Bristol Investment Group Raises $9.6 million for Nutrition 21, Inc.

NEW YORK- Bristol Investment Group, a leading merchant banking firm for growing public and private companies, announced today it has closed on a Convertible Preferred financing of $9.6 million for Nutrition 21, Inc. Bristol completed the financing with several NYC-based institutions including, Midsummer Capital and Cross Atlantic Partners.

Nutrition 21, based in Purchase, NY, is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The function of insulin, the body’s master metabolic hormone, is in part dependent on chromium that must be supplied through diet or supplementation. The Company markets Chromax? chromium picolinate, which is the most studied form of the essential mineral chromium.

“We are very excited to bring growth capital into Nutrition 21 via several very well-respected institutions. We believe that as the science continues to unfold the market for chromium picolinate will expand significantly”, said Arthur Whitcomb, Managing Director of Bristol Investment Group.

About Bristol Investment Group, Inc.

Bristol Investment Group, Inc. is focused on serving the needs of health care, technology and other companies who require growth capital, strategic planning and merger and acquisition advice. The members of the firm have a broad range of experience in raising debt and equity capital, structuring and financing acquisitions, arranging joint ventures and managing communication companies. Mr. Alan Donenfeld, President of Bristol, formed the company in 1990 with the mission of providing a high standard of investment banking services to small and middle market communication companies. Bristol is a broker/dealer firm registered with the National Association of Securities Dealers (NASD) and is member of the Securities Investor Protection Corporation (SIPC). For more information on Bristol Investment Group visit www.BristolDirect.com website.

Back To Press Releases >>>